TCR2 THERAPEUTICS INC. Insider Trading for February 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in TCR2 THERAPEUTICS INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in TCR2 THERAPEUTICS INC. for February 2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 15,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 15.00 | 666,667 | 10,000,005 | 3,370,982 | 2.7 M to 3.4 M (+24.65 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 282,540 | 0 | 2,704,315 | 2.4 M to 2.7 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 2,421,775 | 0 | 2,421,775 | 0 to 2.4 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Option Exercise | C | 0.00 | 2,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Option Exercise | C | 0.00 | 17,500,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Buy | P | 15.00 | 706,666 | 10,599,990 | 4,050,865 | 3.3 M to 4.1 M (+21.13 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Buy | C | 0.00 | 322,901 | 0 | 3,344,199 | 3 M to 3.3 M (+10.69 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM SunStates Fund, L.P. | 10% Owner | Buy | C | 0.00 | 2,825,396 | 0 | 3,021,298 | 195.9 K to 3 M (+1,442.25 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Option Exercise | C | 0.00 | 2,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Option Exercise | C | 0.00 | 17,500,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Buy | P | 15.00 | 706,666 | 10,599,990 | 4,050,865 | 3.3 M to 4.1 M (+21.13 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Buy | C | 0.00 | 322,901 | 0 | 3,344,199 | 3 M to 3.3 M (+10.69 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | MPM BioVentures 2014, L.P. | 10% Owner | Buy | C | 0.00 | 2,825,396 | 0 | 3,021,298 | 195.9 K to 3 M (+1,442.25 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 2,500,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 2,540,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 1,200,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Option Exercise | C | 0.00 | 10,000,001 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | P | 15.00 | 133,333 | 1,999,995 | 536,962 | 403.6 K to 537 K (+33.03 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | P | 15.00 | 166,667 | 2,500,005 | 449,207 | 282.5 K to 449.2 K (+58.99 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | P | 15.00 | 166,667 | 2,500,005 | 166,667 | 0 to 166.7 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | P | 15.00 | 200,000 | 3,000,000 | 200,000 | 0 to 200 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | C | 0.00 | 403,629 | 0 | 403,629 | 0 to 403.6 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | C | 0.00 | 282,540 | 0 | 282,540 | 0 to 282.5 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | C | 0.00 | 410,168 | 0 | 410,168 | 0 to 410.2 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | C | 0.00 | 193,742 | 0 | 193,742 | 0 to 193.7 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Jovan-Embiricos Morana | Director | Buy | C | 0.00 | 1,614,515 | 0 | 1,614,515 | 0 to 1.6 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Upnorth Investment Ltd | 10% Owner | Option Exercise | C | 0.00 | 10,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Upnorth Investment Ltd | 10% Owner | Option Exercise | C | 0.00 | 2,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Upnorth Investment Ltd | 10% Owner | Buy | P | 15.00 | 200,000 | 3,000,000 | 2,137,419 | 1.9 M to 2.1 M (+10.32 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Upnorth Investment Ltd | 10% Owner | Buy | C | 0.00 | 1,614,517 | 0 | 1,937,419 | 322.9 K to 1.9 M (+500.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Upnorth Investment Ltd | 10% Owner | Buy | C | 0.00 | 322,902 | 0 | 322,902 | 0 to 322.9 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 217,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,586,623 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 105,825 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 32,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 57,552 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 15,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,174,998 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 13,599,621 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 907,073 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 325,002 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 493,306 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | P | 15.00 | 1,373,333 | 20,599,995 | 1,569,235 | 195.9 K to 1.6 M (+701.03 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 282,540 | 0 | 2,704,315 | 2.4 M to 2.7 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 35,115 | 0 | 386,270 | 351.2 K to 386.3 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 256,163 | 0 | 2,451,844 | 2.2 M to 2.5 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 17,085 | 0 | 163,532 | 146.4 K to 163.5 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 5,247 | 0 | 57,716 | 52.5 K to 57.7 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 9,291 | 0 | 88,935 | 79.6 K to 88.9 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,421,775 | 0 | 2,421,775 | 0 to 2.4 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 351,155 | 0 | 351,155 | 0 to 351.2 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,195,681 | 0 | 2,195,681 | 0 to 2.2 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 146,447 | 0 | 146,447 | 0 to 146.4 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 52,469 | 0 | 52,469 | 0 to 52.5 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 79,644 | 0 | 79,644 | 0 to 79.6 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Option Exercise | C | 0.00 | 4,375,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Buy | C | 0.00 | 706,351 | 0 | 706,351 | 0 to 706.4 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 217,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,586,623 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 105,825 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 32,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 57,552 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 15,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,174,998 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 13,599,621 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 907,073 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 325,002 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 493,306 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | P | 15.00 | 1,373,333 | 20,599,995 | 1,569,235 | 195.9 K to 1.6 M (+701.03 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 282,540 | 0 | 2,704,315 | 2.4 M to 2.7 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 35,115 | 0 | 386,270 | 351.2 K to 386.3 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 256,163 | 0 | 2,451,844 | 2.2 M to 2.5 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 17,085 | 0 | 163,532 | 146.4 K to 163.5 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 5,247 | 0 | 57,716 | 52.5 K to 57.7 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 9,291 | 0 | 88,935 | 79.6 K to 88.9 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,421,775 | 0 | 2,421,775 | 0 to 2.4 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 351,155 | 0 | 351,155 | 0 to 351.2 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,195,681 | 0 | 2,195,681 | 0 to 2.2 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 146,447 | 0 | 146,447 | 0 to 146.4 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 52,469 | 0 | 52,469 | 0 to 52.5 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 79,644 | 0 | 79,644 | 0 to 79.6 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Option Exercise | C | 0.00 | 4,375,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Gibson Neil W | Director | Buy | C | 0.00 | 706,351 | 0 | 706,351 | 0 to 706.4 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Redmile Group, LLC | 10% Owner | Option Exercise | C | 0.00 | 5,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | Redmile Group, LLC | 10% Owner | Buy | C | 0.00 | 807,256 | 0 | 807,256 | 0 to 807.3 K |